Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 19, 2021

Astellas’ fezolinetant reduced severity of VMS in women in Phase III trial

Astellas Pharma has reported positive topline results from the Phase III pivotal SKYLIGHT 1 and SKYLIGHT 2 clinical trials of an oral non-hormonal compound, fezolinetant, for treating moderate to severe vasomotor symptoms (VMS), specifically hot flashes associated with menopause.

Astellas Pharma has reported positive topline results from the Phase III pivotal SKYLIGHT 1 and SKYLIGHT 2 clinical trials of an oral non-hormonal compound, fezolinetant, for treating moderate to severe vasomotor symptoms (VMS), specifically hot flashes associated with menopause.

An investigational, selective neurokinin-3 receptor (NK3R) antagonist, fezolinetant is in the clinical development stage.

VMS are the most common symptoms of menopause and affect more than 50% of women aged 40 to 64 years.

The ongoing, double-blinded and placebo-controlled SKYLIGHT 1 and SKYLIGHT 2 studies analysed 30mg and 45mg fezolinetant administered once-daily for 12 weeks. It was followed by 40-week active treatment extension periods.

The studies enrolled 1,028 women with moderate to severe VMS at 307 sites in the US, Canada and Europe.

Results showed that both trials met all four co-primary endpoints. It showed a statistically significant reduction from baseline in the frequency and severity of moderate to severe VMS to week four and week 12 for women receiving fezolinetant versus a placebo.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Furthermore, serious treatment-emergent adverse events (TEAE) occurred in less than 2% of patients with headache being the most common TEAE.

The studies are progressing with patients completing a treatment duration of 52 weeks.

The company noted that the detailed results will be reported following the 52-week analyses.

Astellas Pharma senior vice-president Salim Mujais said: “We are encouraged by these results for fezolinetant, which mark the first Phase III data in a new category of selective neurokinin-3 (NK3)-targeted treatments for moderate to severe vasomotor symptoms.

“Vasomotor symptoms can add a significant burden and impact the quality of life for women. We are hopeful that with fezolinetant, we will be able to deliver a novel non-hormonal treatment option.”

Last July, Astellas received a grant from the US National Institutes of Health (NIH) unit to support two Phase I clinical trials of ASP8062 as a maintenance treatment for opioid use disorder (OUD).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU